STIM vs. MDXG, INMD, SSII, BBNX, SIBN, IRMD, CBLL, BFLY, RXST, and AVNS
Should you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include MiMedx Group (MDXG), InMode (INMD), SS Innovations International (SSII), Beta Bionics (BBNX), SI-BONE (SIBN), Iradimed (IRMD), CeriBell (CBLL), Butterfly Network (BFLY), RxSight (RXST), and Avanos Medical (AVNS). These companies are all part of the "medical equipment" industry.
Neuronetics vs. Its Competitors
Neuronetics (NASDAQ:STIM) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.
Neuronetics currently has a consensus price target of $5.50, suggesting a potential upside of 43.98%. MiMedx Group has a consensus price target of $12.50, suggesting a potential upside of 94.70%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than Neuronetics.
Neuronetics received 77 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 83.87% of users gave MiMedx Group an outperform vote while only 68.62% of users gave Neuronetics an outperform vote.
MiMedx Group has a net margin of 23.86% compared to Neuronetics' net margin of -50.09%. MiMedx Group's return on equity of 26.21% beat Neuronetics' return on equity.
In the previous week, MiMedx Group had 8 more articles in the media than Neuronetics. MarketBeat recorded 10 mentions for MiMedx Group and 2 mentions for Neuronetics. MiMedx Group's average media sentiment score of 1.49 beat Neuronetics' score of 0.94 indicating that MiMedx Group is being referred to more favorably in the news media.
Neuronetics has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.
MiMedx Group has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 8.7% of Neuronetics shares are owned by company insiders. Comparatively, 1.7% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
MiMedx Group beats Neuronetics on 13 of the 17 factors compared between the two stocks.
Get Neuronetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neuronetics Competitors List
Related Companies and Tools
This page (NASDAQ:STIM) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy STIM Stock Free STIM Stock Alerts